BlackRock Inc. Sells 163,402 Shares of Spark Therapeutics Inc (NASDAQ:ONCE)

BlackRock Inc. decreased its holdings in shares of Spark Therapeutics Inc (NASDAQ:ONCE) by 5.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,942,896 shares of the biotechnology company’s stock after selling 163,402 shares during the period. BlackRock Inc. owned about 7.60% of Spark Therapeutics worth $335,136,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Bank of Montreal Can grew its holdings in shares of Spark Therapeutics by 84.8% during the fourth quarter. Bank of Montreal Can now owns 6,011 shares of the biotechnology company’s stock worth $236,000 after buying an additional 2,758 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Spark Therapeutics by 16.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after buying an additional 485 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Spark Therapeutics by 47.7% during the fourth quarter. Rhumbline Advisers now owns 42,372 shares of the biotechnology company’s stock worth $1,658,000 after buying an additional 13,686 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Spark Therapeutics by 7.0% during the fourth quarter. SG Americas Securities LLC now owns 4,806 shares of the biotechnology company’s stock worth $188,000 after buying an additional 313 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Spark Therapeutics by 3.2% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 17,696 shares of the biotechnology company’s stock worth $693,000 after buying an additional 546 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $80.00 price target on shares of Spark Therapeutics in a research note on Sunday, February 17th. Mizuho downgraded Spark Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, February 25th. William Blair restated a “buy” rating on shares of Spark Therapeutics in a research note on Tuesday, February 19th. SunTrust Banks downgraded Spark Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 25th. Finally, Jefferies Financial Group downgraded Spark Therapeutics from a “buy” rating to a “hold” rating and raised their price target for the company from $85.00 to $114.50 in a research note on Tuesday, February 26th. One analyst has rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $78.45.

ONCE opened at $100.13 on Thursday. Spark Therapeutics Inc has a 12-month low of $34.53 and a 12-month high of $114.20. The company has a market capitalization of $3.84 billion, a PE ratio of -47.45 and a beta of 2.28. The company has a quick ratio of 5.59, a current ratio of 5.94 and a debt-to-equity ratio of 0.18.

COPYRIGHT VIOLATION WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2019/06/13/blackrock-inc-sells-163402-shares-of-spark-therapeutics-inc-nasdaqonce.html.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.

Recommended Story: Why are gap-down stocks important?

Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply